Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

320 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Peritoneal Dialysis Exit-Site Care Protocols in Portugal and Its Association with Catheter-Related Infections.
Ferreira AC, Fernandes V, Rodrigues A, Abreu CP, Pereira M, Guedes AM, Gomes AM, Cabrita A, Soares C, Pego C, Ferrer F, Bernardo I, Fernandes JC, Assunção J, Oliveira L, Amoedo M, Carvalho MJ, Branco P, Maia P, Chorão R, Castro R, Silva R, Sousa T, Mendes T; Peritoneal Dialysis’ Study Group of the Portuguese Society of Nephrology. Ferreira AC, et al. Among authors: fernandes v, fernandes jc. Blood Purif. 2023;52(4):366-372. doi: 10.1159/000528641. Epub 2023 Jan 26. Blood Purif. 2023. PMID: 36702111
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Impact of osteoporosis and osteoporosis medications on fracture healing: a narrative review.
Chandran M, Akesson KE, Javaid MK, Harvey N, Blank RD, Brandi ML, Chevalley T, Cinelli P, Cooper C, Lems W, Lyritis GP, Makras P, Paccou J, Pierroz DD, Sosa M, Thomas T, Silverman S; Fracture Working Group of the Committee of Scientific Advisors of the International Osteoporosis Foundation, on behalf of the International Osteoporosis Foundation, Société Internationale de Chirurgie Orthopédique et de Traumatologie. Chandran M, et al. Osteoporos Int. 2024 Apr 8. doi: 10.1007/s00198-024-07059-8. Online ahead of print. Osteoporos Int. 2024. PMID: 38587674 Review.
Age-Related Changes in Clinical and Analytical Variables in Chronic Hemodialyzed Patients.
Belo L, Valente MJ, Rocha S, Coimbra S, Catarino C, Lousa I, Bronze-da-Rocha E, Rocha-Pereira P, Sameiro-Faria MD, Oliveira JG, Madureira J, Fernandes JC, Miranda V, Nunes JPL, Santos-Silva A. Belo L, et al. Among authors: fernandes jc. Int J Mol Sci. 2024 Mar 15;25(6):3325. doi: 10.3390/ijms25063325. Int J Mol Sci. 2024. PMID: 38542300 Free PMC article.
320 results